GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Days Sales Outstanding

Organogenesis Holdings (Organogenesis Holdings) Days Sales Outstanding : 78.42 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Days Sales Outstanding?

Organogenesis Holdings's average Accounts Receivable for the three months ended in Dec. 2023 was $85.6 Mil. Organogenesis Holdings's Revenue for the three months ended in Dec. 2023 was $99.7 Mil. Hence, Organogenesis Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 78.42.

The historical rank and industry rank for Organogenesis Holdings's Days Sales Outstanding or its related term are showing as below:

ORGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.35   Med: 54.38   Max: 75.23
Current: 75.23

During the past 9 years, Organogenesis Holdings's highest Days Sales Outstanding was 75.23. The lowest was 51.35. And the median was 54.38.

ORGO's Days Sales Outstanding is ranked worse than
53.15% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs ORGO: 75.23

Organogenesis Holdings's Days Sales Outstanding increased from Dec. 2022 (72.11) to Dec. 2023 (78.42).


Organogenesis Holdings Days Sales Outstanding Historical Data

The historical data trend for Organogenesis Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Days Sales Outstanding Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only 51.35 51.88 54.38 69.58 72.24

Organogenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.11 76.92 72.20 76.88 78.42

Competitive Comparison of Organogenesis Holdings's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Days Sales Outstanding falls into.



Organogenesis Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Organogenesis Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (89.45 + 81.999) / 2 ) / 433.14*365
=85.7245 / 433.14*365
=72.24

Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (89.276 + 81.999) / 2 ) / 99.651*365 / 4
=85.6375 / 99.651*365 / 4
=78.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organogenesis Holdings  (NAS:ORGO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Organogenesis Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings (Organogenesis Holdings) Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Executives
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021